|Bid||1,690.00 x 0|
|Ask||1,743.00 x 0|
|Day's range||1,704.80 - 1,731.20|
|52-week range||1,429.80 - 1,796.40|
|Beta (3Y monthly)||0.37|
|PE ratio (TTM)||18.96|
|Forward dividend & yield||0.92 (5.39%)|
|1y target est||N/A|
PHILADELPHIA-- -- Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency Zejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings GlaxoSmithKline today announced that ...
GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application to the US Food and Drug Administration seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta , for the treatment of asthma in adults.
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.
LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple ...
LONDON--(BUSINESSWIRE)-- Approval based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, traditional, three-drug regimen through 48 weeks, with ...
LONDON--(BUSINESSWIRE)-- Comprehensive data from ATLAS and FLAIR studies presented today at the 2019 Conference on Retroviruses and Opportunistic Infections show investigational long-acting injectable ...